Selected Preclinical and First Clinical Experiences with Magnetically Targeted 4’-Epidoxorubicin in Patients with Advanced Solid Tumors

  • Andreas Stephan Lübbe
  • Christian Bergemann
Chapter

Abstract

Although site-specific direction of drugs within the organism would benefit the patient in many diseases, active drug-targeting has clinically not yet been possible. To overcome some of the problems associated with active drug-targeting, we have developed a magnetic fluid to which drugs, cytokines, DNA-fragments, other molecules and (cytokine-induced killer) cells can be chemically bound so that those agents could be directed and concentrated within the organism by high-energy magnetic fields. In the first part of this chapter, the making and specifications of the ferrofluid are described. In the second part, our experiences with studies of various concentrations of the magnetic fluid in immunosuppressed nude mice, that had been xenotransplanted with human tumors with regard to subjective and objective tolerance are reported. Magnetic drug-targeting, utilizing small amounts of the ferrofluid as a vehicle to concentrate epirubicin locally in tumors is also described. In the third part, a phase-I clinical trial utilizing this approach in patients with advanced and unsuccessfully pretreated cancers or sarcomas is described, followed by a discussion of the specific results in narrow and broad context.

Keywords

Magnetic Field Magnetic Particle Magnetic Fluid Estimate Blood Volume Intraindividual Comparison 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gupta PK, Hung CT (1993). Magnetically controlled targeted chemotherapy. In Microspheres and regional cancer therapy. Willmott N, Daly J (eds.), CRC Press, Boca Raton, Florida, 1–59.Google Scholar
  2. 2.
    Gupta PK (1990). Drug targeting in chemotherapy: a clinical perspective. J. Pharm. Sci. 79, 949–962.CrossRefGoogle Scholar
  3. 3.
    Juliano RL (1991). Targeted Drug Delivery. Berlin, Springer-Verlag.CrossRefGoogle Scholar
  4. 4.
    Leyland-Jones B (1993). Targeted drug-delivery. Sem. Oncol. 20, 12–17.Google Scholar
  5. 5.
    Florence AT, Halbert GW (1985). Drug delivery and targeting. Phys. Technol. 16, 164–192.ADSCrossRefGoogle Scholar
  6. 6.
    Meijer DKF, Jansen RW, Molema G (1992) Drug targeting systems for antiviral agents: options and limitations. Antiviral. Res. 18, 215–258.CrossRefGoogle Scholar
  7. 7.
    Gottstein C, Winkler U, Bohlen H, Diehl V, Engert A(1994). Immunotoxins: is there a clinical value? Ann. Oncol. 5, 97–103.CrossRefGoogle Scholar
  8. 8.
    Sezaki H, Hashida M (1984). Macromolecule drug conjugates in targeted cancer chemotherapy. Crit. Rev. Ther. Drug Carrier Syst. 1, 1–38.Google Scholar
  9. 9.
    Gregoriadis G, Florence AT (1993). Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 45, 15–28.CrossRefGoogle Scholar
  10. 10.
    Ilium L, Davis SS (1987). Polymers in controlled drug delivery. John Wright, Bristol.Google Scholar
  11. 11.
    Widder KJ, Senyei AE, Ranney DF (1979). Magnetically responsive microspheres and other carriers for the biological targeting of antitumor agents. In Advances in Pharmacology and Chemotherapy. Gavattini S, Goldin A, Howkin F, Kopin IJ, Schnitzer RJ (Eds.), Academic Press, New York, 213–239.Google Scholar
  12. 12.
    Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, and Huhn D (1996). Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 56, 4694–4701.Google Scholar
  13. 13.
    Lübbe AS, Bergemann C, Riess H et al (1996). Clinical experiences with magnetic drug targeting: a phase 1 study with 4’-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 56, 4686–4693.Google Scholar
  14. 14.
    Lübbe AS, Huhnt W (1994). Microvessel diameter of human colon adenocarcinoma during acute treatment with serotonin. Int. J. Microcir. 14, 218–225.CrossRefGoogle Scholar
  15. 15.
    Ferruci JT, Stark DD (1990). Iron oxid-enhanced MR imaging of the liver and,spleen: review of the first 5 years. A. J. R. 155, 943–950.Google Scholar
  16. 16.
    Bacon BR, Stark DD, Park CH et al (1987). Ferrite particles: a new magnetic resonance imaging contrast agent. Lack of acute or chronic hepatotoxicity after intravenous administration. J. Lab. Clin. Med. 110, 164–171.Google Scholar
  17. 17.
    Weissleder R, Stark DD, Engelstad BL et al (1989). Superparamagnetic iron oxide: pharmacokinetics and toxicity. A. J. R. 152, 167–173.Google Scholar
  18. 18.
    Van Hecke P, Marchal G, Decrop E, Baert AL (1989). Experimental study of the pharmacokinetics and dose response of ferrite particles used as contrast agent in MRI of the normal liver of the rabbit. Invest. Radiol. 24, 397–399.CrossRefGoogle Scholar
  19. 19.
    Plosker GL, Faulds D (1983). Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45, 788–856.CrossRefGoogle Scholar
  20. 20.
    Bonadonna G, Gianni L, Santora A et al (1993). Drugs ten years later: epirubicin. Ann. Oncol. 4, 359–369.Google Scholar
  21. 21.
    Lübbe AS (1993). Doxorubicin and local hyperthermia in the microcirculation of skeletal muscle. Cancer Chemother. Pharmacol. 31, 295–300.Google Scholar
  22. 22.
    Casazza AM, Giuliani FS (1984). Preclinical properties of epirubicin. In Advances in anthracycline chemotherapy: epirubicin. Bonadonna G (Ed.), Masson, Milano, 31–40.Google Scholar
  23. 23.
    Launchbury AP, Habboubi N (1993). Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat. Rev. 19, 197–228.CrossRefGoogle Scholar
  24. 24.
    Camaggi CM, Strocchi E, Carisi Pet al (1993). Epirubicin metabolism and pharmacokinetics after conventional and high-dose intravenous administration: a cross-over study. Cancer Chemother. Pharmacol. 32, 301–309.Google Scholar
  25. 25.
    Mross K, Maessen P, van der Vijgh WJF et al (1988). Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J. Clin. Oncol. 6, 517–526.Google Scholar
  26. 26.
    Scheulen ME (1989). Klinische Pharmakologie der wöchentlich fraktionierten Behandlung mit Epirubicin. In Wöchentlich fraktioniertes Epirubicin. Klinische Pharmakologie and Indikationen. Scheulen ME, Niederle N (Eds.), Zuckerschwerdt, München, 3–25.Google Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Andreas Stephan Lübbe
    • 1
  • Christian Bergemann
    • 1
  1. 1.Cecilien-KlinikBad LippspringeGermany

Personalised recommendations